Didanosine/Hydroxyurea

去羟肌苷/羟基脲

Report date: 2022/12/07 17:52:21

Base Information

Drug NameDidanosine/Hydroxyurea
Drug Alias Name去羟肌苷羟基脲Hydroxycarbamide and Didanosinehydroxycarbamide/Didanosine羟基脲素去羟肌苷Didanosine and hydroxycarbamide +[13] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionRibonucleotide reductase inhibitorsHuman immunodeficiency virus type 1 reverse transcriptase inhibitors
TargetsHuman immunodeficiency virus type 1 reverse transcriptaseRibonucleotide reductase
Therapy Area/IndicationsHIV Infections
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsYes HydroxyureaDidanosine
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesVirostatics Srl
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesVirostatics Srl
Active IndicationsN/A
Inactive IndicationsHIV Infections

Other Information

ATC CodeN/A
Related LinksN/A